Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Chronic Kidney Disease
Interventions: Predicting choice of dialysis, Behavioral nudges; Other · Behavioral
Lead sponsor: Scaled Insights; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions: Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Endoscopic Procedure, Questionnaire Administration, Sigmoidoscopy; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more

Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions: pegfilgrastim, cisplatin, ifosfamide, paclitaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions: parsaclisib, ruxolitinib, placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 36
States / cities: Anchorage, Alaska • Phoenix, Arizona • Berkeley, California + 29 more

Conditions: Tremor, Essential Tremor, Parkinson Disease, Radiosurgery, Quality of Life
Interventions: Questionnaires / Observational Assessments; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Parkinson Disease, Dementia
Interventions: Active Investigational Treatment ENT-01; Drug
Lead sponsor: Enterin Inc.; Industry
Eligibility: 30 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Fresno, California • Toms River, New Jersey • Dayton, Ohio

Conditions: Type 1 Diabetes
Interventions: TeKnO T1D: Parents; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dry Eye Syndromes
Interventions: IC265 Ophthalmic Solution 1%, Placebo Ophthalmic Solution (Vehicle); Drug
Lead sponsor: Iacta Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Preterm Birth
Interventions: Psychological intervention, Usual Care Group; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vulvar Lichen Sclerosus
Interventions: The CO2RE® System; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • South Burlington, Vermont

Conditions: Lymphoma, Non-Hodgkin
Interventions: Rituximab, BI 695500; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 13
States / cities: Muscle Shoals, Alabama • Bakersfield, California • Burbank, California + 10 more

Conditions: Small Bowel Disease
Interventions: Enteroscopy; Device
Lead sponsor: Aspero Medical, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Baltimore, Maryland • St Louis, Missouri + 1 more

Conditions: Diabetic Foot, DFU, Diabetic Foot Ulcer, Foot Ulcer, Diabetic, Ulcer Foot, Venous Leg Ulcer, Leg Ulcer, Leg Ulcers Venous, Ulcer
Interventions: Standard of Care DFU, Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Standard of Care VLU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU; Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philidelphia, Pennsylvania

Conditions: Pancreatic Neoplasms
Interventions: Ultrasound; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Fragile X Syndrome, Genetic Diseases
Interventions: Lovastatin, Placebo; Drug · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 10 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: RSV Infection
Interventions: RSV 6120/∆NS2/1030s, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 60 Months
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postural Orthostatic Tachycardia Syndrome
Interventions: Shared medical appointment; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Eye Disease, Inflammation, Uveitis
Interventions: Cyclosporin A Implant; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions: bempegaldesleukin, sunitinib, nivolumab, cabozantinib; Biological · Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 20
States / cities: Anchorage, Alaska • Goodyear, Arizona • Little Rock, Arkansas + 16 more

Conditions: Smoking Cessation
Interventions: Telephone-and technology-facilitated treatment protocol, Office-based treatment protocol; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 69 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 114
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 98 more

Conditions: Healthy, Vasodilation, Insulin Resistance, Autonomic Dysfunction, Obesity
Interventions: Carbon dioxide breathing, Neurovascular Coupling, Human insulin; Other · Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 45 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Type 1 Diabetes
Interventions: Psychoeducation to reduce diabetes distress and improve glycemic outcomes; Behavioral
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 14 Years to 25 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • Boston, Massachusetts

Conditions: Stress Disorders, Post-Traumatic, Depression, Sleep
Interventions: Cognitive Behavioral Therapy, Control; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 64 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Behavioral AI to Predict and Increase Peritoneal Dialysis Uptake

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia

Technology Knowledge Optimization in Type 1 Diabetes (TeKnO T1D): Parents

A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants

Philadelphia Preterm Prevention Project

The CO2RE® System for Vulvar Lichen Sclerosus

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

Feasibility of Using Ultrasound to Track Respiration Motion

Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome

Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children

A Shared Medical Appointment Intervention for Quality of Life Improvement in POTS

Cyclosporin Implant to Treat Uveitis

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Technology and Telephone-Based Smoking Cessation

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation

Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)

Managing Sleep Symptoms and Modifying Mechanisms of Traumatic Stress